WELCOME TO THE GVN INTRANET LOG IN Center Survey Step 1 of 5 20% Section 1: General Information & Contact Details Ayuda para traducir Aide à la traduction Institution:(Required)GVN designation(Required) Center of Excellence (CoE) Affiliate None Other (GVN Designation)What type of institution do you represent?(Required) non-profit research institution non-profit organization academic research institution medical institution government agency Other Other (institution Do you Represent)(Required)Address(Required) City State / Province / Region AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Region: (Required)South AmericaCentral AmericaCaribbeanNorth AmericaSouth AsiaEast AsiaCentral AsiaNorth AsiaSoutheast AsiaWest AsiaAustraliaNorth AfricaWest AfricaEast AfricaCentral AfricaSouthern AfricaEuropeName(Required) First Last Primary Contact Person for this Survey:(Required)Title(Required)Email(Required) Phone(Required)WebsiteBio (250 words or less):Highest degree:(Required) MPH PhD MS MD Other Other (Highest Degree) Section 2: Core Virology Expertise & Pathogen Focus Which of the following viral pathogens does your institution have significant expertise with (e.g., routine testing, research, surveillance)? Check the box for all that applies. Adenoviruses Arenaviruses (Lassa, Junín, Machupo, etc.) Chikungunya virus Coronaviruses (SARS-CoV-1, SARS-CoV-2, Middle East respiratory syndrome coronavirus, human coronaviruses 229E, NL63, OC43, or HKU1) Coxsackieviruses Crimean-Congo hemorrhagic fever virus (CCHFV) Cytomegalovirus (CMV) Dengue virus Eastern Equine Encephalitis virus (EEEV) Ebolaviruses Enteroviruses (including EV-D68, poliovirus) Epstein-Barr virus (EBV) Hantaviruses (e.g., Sin Nombre virus, Andes virus) Hepatitis A virus Hepatitis B virus Hepatitis C virus Hepatitis D virus Hepatitis E virus Herpes simplex virus 1 (HSV-1) Herpes simplex virus 2 (HSV-2) Human Immunodeficiency Virus (HIV) Human metapneumovirus (hMPV) Human papillomavirus (HPV) Human T-cell leukemia virus 1 (HTLV-1) Human T-cell leukemia virus 2 (HTLV-2) Influenza A virus Influenza B virus Influenza C virus Influenza D virus JC virus (John Cunningham virus) Lassa virus Marburgviruses Measles virus Monkeypox virus (Mpox) Mumps virus Norovirus Oropouche virus Parainfluenza viruses (types 1–4) Rabies virus Respiratory syncytial virus (RSV) Rhinoviruses Rift Valley fever virus Rotavirus Rubella virus Simian Foamy Virus Smallpox (Variola virus) Tick-borne encephalitis virus (TBEV) Varicella-zoster virus (VZV) Venezuelan Equine Encephalitis virus (VEEV) West Nile virus (WNV) Western Equine Encephalitis virus (WEEV) Yellow Fever virus Zika virus Other: please specify Name up to three virologists working with these viruses.Other (Viral Pathogens) Section 3: Infrastructure, Resources & Quality What Biosafety Level (BSL) facilities are at your institution? (Select all that apply) BSL-1 BSL-2 BSL-3 BSL-4 N/A (No virology work performed requiring specific BSLs) Does your center possess any of the following state-of-the-art facilities or specialized equipment highly relevant to virology research/diagnostics? (Select all that apply) Cryo-Electron Microscopy (Cryo-EM) suite Next-generation sequencing (NGS) platforms (e.g., Illumina NovaSeq, Oxford Nanopore PromethION) Advanced flow cytometers (e.g., multi-parameter cell sorters) Automated liquid handling systems High-throughput screening platforms Mass spectrometry for proteomics/metabolomics Dedicated animal facility (specify type if applicable, e.g., ABSL-3) Other significant equipment/facility) Other (Equipment)Approximate the number of full-time equivalent (FTE) staff dedicated to virology activities (including researchers, technicians, bioinformaticians, etc.). <10 11-30 31-60 61-99 100+ Is your laboratory currently accredited by a recognized body for its virology operations? Yes, nationally accredited (e.g., CLIA, ISO 15189, CAP, etc.) Yes, internationally accredited (e.g., WHO-recognized, ISO 17025, etc.) In process of seeking accreditation Not currently accredited Other Does your laboratory have a documented Quality Management System (QMS) for virology operations? Yes No Are you involved in mentorship programs or capacity-building initiatives for other laboratories (e.g., in your region, nationally, or globally)? Yes, at the regional level Yes, at the national level Yes, at the global/international level Yes, at multiple levels (please specify) No Not sure Yes, at multiple levels (please specify) [Are you involved in any community engagement activities related to viral disease prevention, awareness, or education? Yes No Not sure Yes (Explain Community Engagement)During an outbreak, what is your institution’s surge capacity for clinical care? Please indicate the maximum number of additional patients your facility can accommodate per day for outbreak-related illness. Fewer than 10 patients/day 10–49 patients/day 50–99 patients/day 100–249 patients/day 250+ patients/day Not applicable Not sure During an outbreak, what is your institution’s surge capacity for diagnostic testing? Please indicate the maximum number of samples/tests your institution can process per day during peak outbreak response. Less than 100 tests/day 100–499 tests/day 500–999 tests/day 1,000–4,999 tests/day 5,000–9,999 tests/day 10,000+ tests/day Not applicable Not sure During an outbreak, what is your institution’s surge capacity related to vaccines? We do not produce vaccines Less than 10,000 doses/week 10,000–99,999 doses/week 100,000–499,999 doses/week 500,000+ doses/week Not sure Vaccine Delivery/Administration Capacity. How many doses can your institution administer (or distribute through partners) per week? Less than 1,000 doses/week 1,000–9,999 doses/week 10,000–49,999 doses/week 50,000+ doses/week Not sure Section 4: Surveillance, Epidemiology & Response Does your center perform in-house viral genomic sequencing? (Check all that apply) Whole-genome sequencing Targeted sequencing (e.g., amplicon-based) Metagenomic sequencing No in-house sequencing performed [if selected skip to section 5] Outsourced to external lab/partner Other (please specify): Other (Center Perform in-house viral genomic sequencing)Does your center have in-house bioinformatics expertise for viral genomic data analysis? (Check all that apply) Phylogenetic analysis Variant calling Genome assembly Data visualization / dashboards No in-house bioinformatics expertise Other (please specify): Other (In-house bioinformatics expertise for viral genomic data analysis).Do you contribute sequence data to any of the following databases? (Check all that apply) GISAID GenBank / NCBI EMBL-EBI Local or national database Do not routinely submit data Other (please specify): Other (Contribute sequence data to any of the following databases)Approximately how many viral genomes does your center sequence per year? < 100 100–499 500–1,999 2,000–9,999 10,000+ Not applicable / sequencing not performed What sequencing platforms does your center use? (Check all that apply) Illumina (e.g., MiSeq, NextSeq, NovaSeq) Oxford Nanopore Technologies (e.g., MinION, GridION) PacBio Ion Torrent Sanger sequencing Other (please specify): Other (Sequencing platforms does your center use)Does your laboratory actively participate in viral disease surveillance programs (e.g., sentinel surveillance, syndromic surveillance)? Yes No Yes (Explain Viral Disease Surveillane)Does your laboratory have a formally designated role in emergency response operations related to viral outbreaks or public health emergencies (e.g., inclusion in national or regional response plans)? Yes — formally designated in a national plan Yes — formally designated in a regional/provincial plan Yes — informally engaged in response efforts No — not currently designated, but interested in participating No — not involved in emergency response Other If “Yes,” please briefly describe your role and any agencies or partners you coordinate with:Does your institution currently conduct, or have the capacity to conduct clinical trials related to virology? Yes — Currently running one or more virology-related clinical trials Yes — Have the infrastructure and regulatory approvals, but not currently running a virology trial No — Do not currently conduct virology-related trials and lack infrastructure Not sure Please list key pathogens or trial types in the space below. Section 5: Strategic Outlook & Challenges Do you have plans to grow your capacity in any particular viruses in the next 12 months? If so which ones? Yes No Yes (Capacity to grow - Which ones) Arboviruses Respiratory viruses Hemorrhagic fever viruses Enteric viruses Oncogenic viruses Zoonotic viruses Are there any new machines or diagnostic platforms currently on order or planned for acquisition at your center within the next 12 months? No new equipment currently on order Yes — PCR platforms (e.g., qPCR, digital PCR) Yes — Next-generation sequencers (e.g., Illumina, Oxford Nanopore, PacBio) Yes — Serology or immunoassay analyzers Yes — Point-of-care diagnostic devices Yes — High-throughput screening or automation systems Yes — Biosafety or containment infrastructure upgrades Other (please specify): Not sure Please list the specific equipment (make/model if known), estimated arrival date, and intended use:Are there specific viral pathogens of concern in your region? (Select all that apply and briefly explain why, if applicable.) Arboviruses (e.g., Dengue, Zika, Chikungunya, Oropouche) Respiratory viruses (e.g., SARS-CoV-2, Influenza, RSV) Hemorrhagic fever viruses (e.g., Lassa, Ebola, Marburg) Enteric viruses (e.g., Norovirus, Enteroviruses) Zoonotic spillover risks (e.g., Nipah, novel coronaviruses) Other (please specify): What makes these viruses particularly concerning in your region? Other (new machines or diagnostic platforms)What makes these viruses particularly concerning in your region?Please briefly describe how these challenges impact your work or ability to respond to emerging viral threatsIs your center currently using artificial intelligence (AI) applications in any aspect of your work? (Select all that apply and provide brief details.) No, we are not currently using AI Yes, for diagnostics (e.g., image analysis, test interpretation) Yes, for surveillance and outbreak prediction Yes, for genomic analysis (e.g., sequence alignment, variant calling) Yes, for drug or vaccine discovery Yes, for data integration or decision support systems Yes, for administrative or operational efficiency Other (please specify): Please describe any specific AI tools, platforms, or partnerships you're using: Other (Center currently using AI applications in any aspect of your work)Please describe any specific AI tools, platforms, or partnerships you're using:
